Agassandian M, Shurin GV, Ma Y., Shurin M. C-reactive protein and lung diseases. Int J Biochem Cell Biol.2014;53:77–88. doi: 10.1016/j.biocel.2014.05.016
an Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin forscreening of patients with suspected inflammatory bowel disease: diag-nostic meta-analysis.BMJ. 2010;341:c3369
Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011; 43: 246–252.
Annahazi, A.; Molnar T., Farkas K., Rosztóczy A., Inczefi O., Földesi I. et al., “Fecal MMP-9: a new noninvasive differential diagnostic and activity marker in ulcerative colitis” Inflammatory Bowel Diseases, vol. 19, no. 2, pp. 316–320, 2013.
Ashton, J. J.; Mossotto E., Ennis S., Beattie R. M..Personalising medicine in inflammatory bowel disease—current and future perspectives. Transl Pediatr 2019;8(1):56-69 .
Béres N.J., Kiss Z., Sztupinszki Z.,Lendvai G., Arató A., Sziksz E., et al., “Altered mucosal expression of microRNAs in pediatric patients with inflammatory bowel disease,” Digestive and Liver Disease, vol. 49, no. 4, pp. 378–387, 2017
Chen, X. (2009). Small rnas and their roles in plant development. Annual Review of Cell and Developmental, 25:21–44.
Chung-Faye G., Hayee B., Maestranzi S., Donaldson N., Forgacs I., and Sherwood R.,“Fecal M2-pyruvate kinase(M2-PK): a novel marker of intestinal inflammation,”Inflam-matory Bowel Diseases, vol. 13, no. 11, pp. 1374–1378, 2007
Click, B., Vargas E.J., Anderson A.M., Proksell S., Koutroubakis I.E., et al. Silent crohn’s disease: asymptomatic patients with elevated C-reactive protein are at risk for subsequent hospitalization. Inflamm. Bowel Dis. 21, 2254–2261 (2015)
Czub, E.; K.-H. Herzig, Szaflarska-Popawska A, Chlebowczyk U.G.,Landowski P. et al. “Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease.”Scandinavian Journal of Gastroenterology, vol. 42, no. 10,pp. 1147–1150, 2007
Czub, E.; K.-H. Herzig, Szaflarska-Popawska A, Chlebowczyk U.G.,Landowski P et al. “Comparison of fecal pyruvate kinase isoform M2 and calprotectin inassessment of pediatric inflammatory bowel disease severityand activity,”Acta Biochimica Polonica, vol. 61, no. 1,pp. 99–102, 2014.
D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogatemarker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis.2012;18:2218–2224
D’Incà R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk ininflammatory bowel disease?Am J Gastroenterol.2008;103:2007–2014.
De Lange, K.M.; Moutsianas, L.; Lee, J.C.; Lamb, C.A.; Luo, Y.; Kennedy, N.A.; Jostins, L.; Rice, D.L.; Gutierrez-Achury, J.; Ji, S.G.; et al. Genome-wide association study implicates immune activation of multipleintegrin genes in inflammatory bowel disease.Nat. Genet.2017,49, 256–261.
Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopicactivity index and biological inflammatory markers in clinically activeCrohn’s disease with normal C-reactive protein serum level. Inflamm Bowel Dis.2007;13:1100–1105.
Duvoisin, G.; Robert N. Lopez, Andrew S. Day, Daniel A. Lemberg, Richard B. Gearry, and Steven T. Leach Novel Biomarkers and the Future Potential of Biomarkers inInflammatory Bowel Disease. HindawiMediators of InflammationVolume 2017, Article ID 1936315, 9 pageshttps://doi.org/10.1155/2017/193631
Ellinghaus, D.; Jostins, L.; Spain, S.L.; Cortes, A.; Bethune, J.; Han, B.; Park, Y.R.; Raychaudhuri, S.; Pouget, J.G.; Hubenthal, M.; et al. Analysis of five chronic inflammatory diseases identifies 27 new associations andhighlights disease-specific patterns at shared loci.Nat. Genet.2016,48, 510–518.
Eulalio, A., Huntzinger, E., and Izaurralde, E. (2008). Getting to the root of mirna-mediated gene silencing. Cell, 132(1):9–14.
Falvey, J. D. et al. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm. Bowel Dis. 21, 824–831 (2015).
Farkas, K.; Z. Sarodi, A. Balint et al., “The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases,” Journal of Crohn's & Colitis, vol. 9, no. 3, pp. 231–237, 2015
Filipowicz, W., Bhattacharyya, S. N., and Sonenberg, N. (2008). Mechanisms of post-transcriptional regulation by micrornas: are the answers in sight? Nature Reviews Genetics, 9(2):102–114
Fineberg, S. K., Kosik, K. S., and Davidson, B. L. (2009). Micrornas potentiate neural development. Neuron, 64(3):303–309.
Florin TH, Paterson EW, Fowler EV, et al. Clinically active Crohn’sdisease in the presence of a low C-reactive protein. Scand J Gastroenterol.2006;41:306–311
Friedman, R. C., Farh, K. K.-H., Burge, C. B., and Bartel, D. P. (2009). Most mammalian mrnas are conserved targets of micrornas. Genome research, 19(1):92– 105
Fuks, F. (2005). Dna methylation and histone modifications: teaming up to silence genes. Current opinion in genetics & development, 15(5):490–495
Gao, Q.; M. J. Meijer, F. J. Kubben et al., “Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases,” Digestive and Liver Disease, vol. 37, no. 8, pp. 584–592, 2005
Gao, Q.; M. J. Meijer, U. G. Schluter et al., “Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn’s disease,” Inflammatory Bowel Diseases, vol. 13, no. 6, pp. 693–702, 2007.
Gecse, K. B. et al. Impact of disease location on fecal calprotectin levels in Crohn’s disease. Scand. J. Gastroenterol. 50, 841–847 (2015).
Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin andlactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis.2009;15:1190–1198.
Guay, C. & Regazzi, R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol 9, 513–521, doi:10.1038/nrendo.2013.86 (2013).
Gutierrez A, Holler E, Zapater P, et al. Antimicrobial peptide response toblood translocation of bacterial DNA in Crohn’s disease is affected byNOD2/CARD15 genotype. Inflamm Bowel Dis.2011;17:1641–1650
Hardt, P. D.; S. Mazurek, M. Toepler et al. “Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool forcolorectal cancer.”British Journal of Cancer, vol. 91, no. 5,pp. 980–984, 2004.
Haug U.; M. N. Wente, C. M. Seiler, D. Rothenbacher, M. W. Buchler, and H. Brenner. “Tumor M2 pyruvate kinase as astool marker for colorectal cancer: stability at room tempera-ture and implications for application in the screening setting,”Clinical Chemistry, vol. 52, no. 4, pp. 782–784, 2006.
Henderson, P. et al. Serum C-reactive protein and CRP genotype in pediatric inflammatory bowel disease: influence on phenotype, natural history, and response to therapy. Inflamm. Bowel Dis. 21, 596–605 (2015)
Hong SN, Park C, Park SJ, et al. Deep resequencing of 131 Crohn’s diseaseassociated genes in pooled DNA confirmed three reported variants andidentified eight novel variants. Gut 2016; 65:788–796.
Hyams J.; J. Markowitz, A. Otley et al.“Evaluation of thepediatric crohn disease activity index: a prospective multicen-ter experience,”Journal of Pediatric Gastroenterology andNutrition, vol. 41, no. 4, pp. 416–421, 2005.
Jones, J. et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin. Gastroenterol. Hepatol. 6, 1218–1224 (2008)
Judd, T. A.; A. S. Day, D. A. Lemberg, D. Turner, and S. T.Leach,“Update of fecal markers of inflammation in inflamma-tory bowel disease,”Journal of Gastroenterology and Hepatol-ogy, vol. 26, no. 10, pp. 1493–1499, 2011.
Kalla R, Ventham NT, Kennedy NA, et al. Gut Published Online First: December 15, 2014 - doi:10.1136/ gutjnl-2014-307891
Kapel, N.; N. Benahmed, A. Morali et al., “Fecal betadefensin-2 in children with inflammatory bowel diseases,” Journal of Pediatric Gastroenterology & Nutrition, vol. 48, no. 1, pp. 117–120, 2009
Kennedy, N. A. et al. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Aliment. Pharmacol. Ther. 40, 1313–1323 (2014).
Kiss, L. S. et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease. Aliment. Pharmacol. Ther. 34, 911–922 (2011).
Kiss, L. S. et al. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn’s disease: a marker for patient classification? Inflamm. Bowel Dis. 18, 1647–1654 (2012).
Kofla-Dlubacz, A.; M. Matusiewicz, M. Krzystek-Korpacka, and B. Iwanczak, “Correlation of MMP-3 and MMP-9 with Crohn’s disease activity in children,” Digestive Diseases and Sciences, vol. 57, no. 3, pp. 706–712, 2012.
Kofla-Dlubacz, A.; M. Matusiewicz, E. Krzesiek, L. Noga, and B. Iwanczak, “Metalloproteinase-3 and -9 as novel markers in the evaluation of ulcerative colitis activity in children,” Advances in Clinical and Experimental Medicine, vol. 23, no. 1, pp. 103–110, 2014
Kolho, K. L.; T. Sipponen, E. Valtonen, and E. Savilahti, “Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease,” International Journal of Colorectal Disease, vol. 29, no. 1, pp. 43–50, 2014
Kopylov U, Rosenfeld G, Bressler B, et al. Clinical utility of fecalbiomarkers for the diagnosis and management of inflammatory boweldisease.Inflamm Bowel Dis.2014;20:742–756.
Lasson A, Stotzer POO, Ohman L, et al. The intra-individual variabilityof faecal calprotectin: a prospective study in patients with active ulcerative colitis.J Crohns Colitis. 2015;9:26–32
Lewis JD. The utility of biomarkers in the diagnosis and therapy ofinflammatory bowel disease.Gastroenterology. 2011;140:1817–1826.e2.
Lin JF, Chen JM, Zuo JH, et al. Meta-analysis: fecal calprotectin forassessment of inflammatory bowel disease activity.Inflamm Bowel Dis.2014;20:1407–1415.
Liu, J. Z., van Sommeren, S., Huang, H., Ng, S. C., Alberts, R., Takahashi, A., et al. (2015). Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat. Genet. 47 (9), 979–986. doi: 10.1038/ng.3359
Liu L.; J. He, X. Wei et al., “MicroRNA-20a-mediated loss of autophagy contributes to breast tumorigenesis by promoting genomic damage and instability,” Oncogene, vol. 36, no. 42, pp. 5874–5884, 2017
Louis, E. et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142, 63–70 e65 (2012).
Louis,E.; C. Ribbens, A. Godon et al., “Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease,” Clinical and Experimental Immunology, vol. 120, no. 2, pp. 241–246, 2000.
Lu, Z.-J. ;J.-J. Wu, W.-L. Jiang et al., “MicroRNA-155 promotes the pathogenesis of experimental colitis by repressing SHIP-1 expression,” World Journal of Gastroenterology, vol. 23, no. 6, pp. 976–985, 2017.
Makitalo, L.; H. Rintamaki, T. Tervahartiala, T. Sorsa, and K. L. Kolho, “Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-alpha therapy in pediatric inflammatory bowel disease,” Scandinavian Journal of Gastroenterology, vol. 47, no. 7, pp. 785–794, 2012.
Manfredi, M. A.; D. Zurakowski, P. A. Rufo, T. R. Walker, V. L. Fox, and M. A. Moses, “Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 14, no. 8, pp. 1091–1096, 2008
Masoodi, I. ; R. Kochhar, U. Dutta et al., “Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis,”Journal of Gastroenterology and Hepatology, vol. 24, no. 11, pp. 1768–1774, 2009.
Masoodi,I.; R. Kochhar, U. Dutta et al., “Evaluation of fecal myeloperoxidase as a biomarker of disease activity and severity in ulcerative colitis,” Digestive Diseases and Sciences, vol. 57, no. 5, pp. 1336–1340, 2012
Matsumoto A., Nakayama K.I., Hidden Peptides Encoded by Putative Noncoding RNAs. Cell Structure and Function. 2018; 43 (1) : 75-83
McGovern DP, Kugathasan S, Cho JH. Genetics of inflammatory boweldiseases. Gastroenterology 2015; 149:1163–1176.
Medina C.; and M. W. Radomski, “Role of matrix metalloproteinases in intestinal inflammation,” The Journal of Pharmacology and Experimental Therapeutics, vol. 318, no. 3, pp. 933–938, 2006
Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105:10513–8.
Mosli, M. H. et al. C-Reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am. J. Gastroenterol. 110, 802–819 (2015).
Nauseef, W. M. and H. L. Malech, “Analysis of the peptide subunits of human neutrophil myeloperoxidase,” Blood, vol. 67, no. 5, pp. 1504–1507, 1986.
Palmieri O., Teresa Maria Creanza , Fabrizio Bossa , Tiziana Latiano , Giuseppe Corritore , Orazio Palumbo , Giuseppina Martino , Giuseppe Biscaglia , Daniela Scimeca , Massimo Carella, Nicola Ancona , Angelo Andriulli1 and Anna Latiano.Functional Implications of MicroRNAs in Crohn’s Disease Revealed by Integrating MicroRNA and Messenger RNA Expression Profiling. Int. J. Mol. Sci. 2017, 18, 1580; doi:10.3390/ijms18071580
Petersen BS, Spehlmann ME, Raedler A, et al.Whole genome and exomesequencing of monozygotic twins discordant for Crohn’s disease. BMCGenomics 2014; 15:564.
Peterson, C. G. B. ; E. Eklund, Y. Taha, Y. Raab, and M. Carlson, “A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease,” The American Journal of Gastroenterology, vol. 97, no. 7, pp. 1755–1762, 2002.
Peyrin-Biroulet, L.; Julián Panés, William J. Sandborn, Séverine Vermeire,Silvio Danese, Brian G. Feagan, Jean-Frédéric Colombel, Stephen B. Hanauer S,Beth Rycroft.Defining disease severity in inflammatory bowel diseases: current and futuredirections. Clinical Gastroenterology and Hepatology,2016;14:348-354
Ramasundara,M.; S. T. Leach, D. A. Lemberg, and A. S. Day, “Defensins and inflammation: the role of defensins in inflammatory bowel disease,” Journal of Gastroenterology and Hepatology, vol. 24, no. 2, pp. 202–208, 2009
Reinisch, W. et al. Factors associated with short- and long-term outcomes of therapy for Crohn’s disease. Clin. Gastroenterol. Hepatol. 13, 539–547.e2 (2015).
Reinisch, W., Wang, Y., Oddens, B. J. & Link, R. C-Reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn’s disease: a post-hoc analysis from ACCENT I. Aliment. Pharmacol. Ther. 35, 568–576 (2012).
Røseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activityin ulcerative colitis by faecal calprotectin, a novel granulocyte markerprotein.Digestion. 1997;58:176–180.
Roszak, D.; M. Galecka, W. Cichy, and P. Szachta,“Determi-nation of faecal inflammatory marker concentration as anoninvasive method of evaluation of pathological activityin children with inflammatory bowel diseases,”Advancesin Medical Sciences, vol. 60, no. 2, pp. 246–252, 2015.
Rutgeerts, P. et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 11 7, 761–769 (1999).
Salem M, Ammitzboell M, Nys K,et al.ATG16L1: a multifunctional suscept-ibility factor in Crohn disease. Autophagy 2015; 11:585–594
Salmela, M. T.; T. T. MacDonald, D. Black et al., “Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation,” Gut, vol. 51, no. 4, pp. 540–547, 2002.
Sangfelt,P.; M. Carlson, M. Thorn, L. Loof, and Y. Raab, “Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proctitis,” The American Journal of Gastroenterology, vol. 96, no. 4, pp. 1085–1090, 2001.
Saunders MA, Liang H, Li W-H. Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci USA 2007;104:3300–5
Scarpa M, D’Incà R, Basso D, et al. Fecal lactoferrin and calprotectinafter ileocolonic resection for Crohn’s disease.Dis Colon Rectum.2007;50:861–869.
Sipponen T, Björkesten CGAF, Färkkilä M, et al. Faecal calprotectin andlactoferrin are reliable surrogate markers of endoscopic response duringCrohn’s disease treatment.Scand J Gastroenterol.2010;45:325–331
Solberg IC, Hoivik ML, Cvancarova M, et al. Risk matrix model forprediction of colectomy in a population-based study of ulcerative colitispatients (the IBSEN study).Scand J Gastroenterol.2015;50:1456–1462.
Soroosh A. , Marina Koutsioumpa , Charalabos Pothoulakis , Dimitrios Iliopoulos.Functional role and therapeutic targeting of microRNAs in Inflammatory Bowel Disease Am J Physiol Gastrointest Liver Physiol (November 16, 2017). doi:10.1152/ajpgi.00268.2017
Tahamtan A, Teymoori-Rad M, Nakstad B and Salimi V (2018) Anti-Inflammatory MicroRNAs and Their Potential for Inflammatory Diseases Treatment. Front. Immunol. 9:1377. doi: 10.3389/fimmu.2018.01377
Tang, Q.;Q. Ji, W. Xia et al.,“Pyruvate kinase M2 regulates apoptosis of intestinal epithelial cells in Crohn’s disease,”Digestive Diseases and Sciences, vol. 60, no. 2, pp. 393–404, 2015.
Theede K, Holck S, Ibsen P, et al. Fecal calprotectin predicts relapse andhistological mucosal healing in ulcerative colitis.Inflamm Bowel Dis.2016;22:1042–1048
Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers ofinflammation and Rome criteria to distinguish organic from nonorganicintestinal disease.Gastroenterology. 2002;123:450–460
Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis.Gut. 1996;38:905–910.
Ventham NT, Kennedy NA, Nimmo ER, Satsangi J. Beyond Gene Discovery in Inflammatory Bowel Disease: The Emerging Role of Epigenetics Gastroenterology. 2013 Aug;145(2):293-308. doi: 10.1053/j.gastro.2013.05.050. Epub 2013 Jun 8
Viennois E., Zhao Y. , Kwon Han M., Xiao B., Zhang M., Prasad M., et al. Serum miRNA signature diagnoses and discriminates murine colitis subtypes and predicts ulcerative colitis in humans. Scientific Reports | 7: 2520 | DOI:10.1038/s41598-017-02782-1
Walsh, A. J. ;Robert V. Bryant and Simon P. L. Travis Current best practice for disease activity assessment in IBD.GASTROENTEROLOGY & HEPATOLOGY VOLUME 13 | OCTOBER 2016 |567
Wang C. and Chen J. MicroRNAs as therapeutic targets in intestinal diseases. ExRNA (2019) 1:23 https://doi.org/10.1186/s41544-019-0026-9
Wang S., Yan Huang , Cili Zhou , Huangan Wu , Jimeng Zhao , Luyi Wu,1 Min Zhao , Fang Zhang , and Huirong Liu.Gastroenterology Research and Practice Volume 2018, Article ID 7565076, 10 pages https://doi.org/10.1155/2018/7565076
Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calpro-tectin improves monitoring and detection of recurrence of Crohn’sdiseaseafter surgery.Gastroenterology. 2015;148:938–947.e1.
Wu F, Zhang S, Dassopoulos T, et al. Identification of microRNAs associated with ileal and colonic Crohn’s disease. Inflamm Bowel Dis. 2010;16:1729-1738.
Yang L., Yaoyao Bian, Zhengjun Li, Yan Yan , Junyi Li , Wenlin Li , Li Zeng. Identification of potential biomarkers and pathways in ulcerative colitis with combined public mRNA and miRNA expression microarray data analysis J Gastrointest Oncol 2019;10(5):847-858 | http://dx.doi.org/10.21037/jgo.2019.06.06
Yang, D. H. et al. Usefulness of C-reactive protein as a disease activity marker in Crohn’s disease according to the location of disease. Gut Liver 9, 80–86 (2015).
Yi JH, Wang D, Li ZY, et al. C-reactive protein as a prognostic factor forhuman osteosarcoma: a meta-analysis and literature review. PLoS One.2014;9:e94632.
Yordanova M., Gerova D., Atanassova A., Galunska B. Adenosine Deaminase as a Useful Biomarker for Diagnosis and Monitoring of Inflammatory Bowel Disease. Clinical Laboratory.2020,66 (7), 1315-1323
Zeng Z, Mukherjee A and Zhang H (2019) From Genetics to Epigenetics, Roles of Epigenetics in Inflammatory Bowel Disease. Front. Genet. 10:1017. doi: 10.3389/fgene.2019.01017
